Get the Stockscreener App
50.92
3.60%
1.77
After Hours:
51.24
0.32
+0.63%
Veracyte Inc stock is traded at $50.92, with a volume of 1.77M.
It is up +3.60% in the last 24 hours and up +32.33% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$49.15
Open:
$49.66
24h Volume:
1.77M
Relative Volume:
1.71
Market Cap:
$4.06B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
46.88
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
+3.41%
1M Performance:
+32.33%
6M Performance:
+17.82%
1Y Performance:
+91.14%
1-Day Range:
$49.42
$52.45
1-Week Range:
$46.04
$52.45
52-Week Range:
$22.61
$52.45
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
50.92 | 3.92B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte (VCYT) director Jens Holstein awarded 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Eliav Barr receives 5,272 restricted stock units - Stock Titan
Director at Veracyte (VCYT) receives grant of 5,272 restricted stock units - Stock Titan
Evan Jones of Veracyte (NASDAQ: VCYT) receives 5,272 restricted stock units - Stock Titan
Veracyte (VCYT) director Robert Epstein receives 5,272-share RSU grant - Stock Titan
Veracyte (VCYT) director awarded 5,272 RSUs vesting over one year - Stock Titan
Veracyte, Inc. 2023 Equity Incentive Plan Amended – SEC 8-K Filing Details and Company Information - Minichart
FMR LLC's Strategic Acquisition of Veracyte Inc Shares - GuruFocus
Veracyte (VCYT) investors back 3.5M-share equity plan increase and elect full board - Stock Titan
Veracyte (NASDAQ:VCYT) Hits New 12-Month HighHere's Why - MarketBeat
Why Veracyte (VCYT) is a top momentum stock for the long term - MSN
Here's why Veracyte (VCYT) is a strong growth stock - MSN
Veracyte Inc Annual Shareholders Meeting Transcript - GuruFocus
Here's how much a $1000 investment in Veracyte made 10 years ago would be worth today - MSN
Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Veracyte, Inc. $VCYT Shares Sold by Amova Asset Management Americas Inc. - MarketBeat
Veracyte, Inc. $VCYT Shares Sold by GW&K Investment Management LLC - MarketBeat
Veracyte Inc (VCYT) Stock Down 3.0% but Still Overvalued -- GF S - GuruFocus
Veracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Why is Veracyte (VCYT) up 18.2% since last earnings report? - MSN
Veracyte (VCYT) Is Up 9.4% After New Phase III Data Validates Prosigna Chemotherapy-Guidance Role – Has The Bull Case Changed? - Sahm
FMR LLC holds 8.06M Veracyte (VCYT) shares, representing 10.1% - Stock Titan
Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing - marketscreener.com
Veracyte EVP Annie McGuire sells $158k in company stock By Investing.com - Investing.com UK
Veracyte CFO Rebecca Chambers sells $177,082 in company stock By Investing.com - Investing.com Canada
Veracyte global chief commercial off sells $699,732 in stock By Investing.com - Investing.com South Africa
Veracyte CEO Marc Stapley sells $6.9m in company shares By Investing.com - Investing.com South Africa
Veracyte CFO Rebecca Chambers sells $177,082 in company stock - Investing.com
Veracyte (VCYT) CFO trades shares as RSUs vest and 10b5-1 plan executes - Stock Titan
Veracyte (VCYT) CAO reports 1,361 shares withheld for RSU tax obligations - Stock Titan
Veracyte global chief commercial off sells $699,732 in stock - Investing.com
Veracyte CEO Marc Stapley sells $6.9m in company shares - Investing.com
[144] VERACYTE, INC. SEC Filing - stocktitan.net
VCYT (NASDAQ) insider 10b5-1 sale of 10,204 shares; 3,176 RSUs registered - Stock Titan
VCYT Stock Price, Quote & Chart | VERACYTE INC (NASDAQ:VCYT) - ChartMill
How Veracyte (VCYT) Investors Can Read The Latest Unchanged Analyst Call - Yahoo Finance
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report? - Yahoo Finance
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate CancerSlideshow (NASDAQ:VCYT) 2026-06-03 - Seeking Alpha
Veracyte, Inc. (VCYT) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
Veracyte stock price target maintained at $42 by Canaccord on study results - Investing.com South Africa
Veracyte (VCYT) Launches Prosigna Breast Cancer Risk Test in the U.S. - GuruFocus
Wolfe Research initiates Veracyte stock coverage with Outperform rating By Investing.com - Investing.com South Africa
Wolfe Research initiates Veracyte stock coverage with Outperform rating - Investing.com
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chambers Rebecca | Chief Financial Officer |
Jun 04 '26 |
Sale |
49.73 |
3,561 |
177,083 |
173,280 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Option Exercise |
36.60 |
138,051 |
5,052,667 |
578,545 |
| Stapley Marc | Chief Executive Officer |
Jun 04 '26 |
Sale |
50.12 |
138,051 |
6,919,585 |
440,494 |
| Leite John | Global Chief Commercial Off |
Jun 04 '26 |
Sale |
50.07 |
13,975 |
699,732 |
132,305 |
0.56%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):